ICON Public Limited (NASDAQ:ICLR - Get Free Report) has earned a consensus rating of "Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $346.09.
Several research analysts have weighed in on the stock. Evercore ISI lowered their target price on shares of ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird lowered their price target on ICON Public from $368.00 to $340.00 and set an "outperform" rating on the stock in a report on Friday, September 20th. Redburn Atlantic initiated coverage on ICON Public in a report on Monday, October 14th. They set a "neutral" rating and a $311.00 price objective for the company. StockNews.com lowered ICON Public from a "buy" rating to a "hold" rating in a report on Thursday, September 19th. Finally, Truist Financial cut their price target on ICON Public from $383.00 to $363.00 and set a "buy" rating for the company in a research note on Monday, October 14th.
Check Out Our Latest Stock Analysis on ICLR
ICON Public stock opened at $297.72 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The business has a 50 day simple moving average of $303.72 and a 200-day simple moving average of $312.36. ICON Public has a 12 month low of $221.20 and a 12 month high of $347.72. The stock has a market capitalization of $24.56 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22.
ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm had revenue of $2.10 billion during the quarter, compared to analysts' expectations of $2.14 billion. During the same period in the prior year, the company posted $2.96 earnings per share. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. Equities analysts predict that ICON Public will post 14.54 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of ICLR. Riverview Trust Co purchased a new position in ICON Public in the first quarter valued at about $31,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ICON Public during the 2nd quarter valued at about $54,000. GAMMA Investing LLC lifted its position in ICON Public by 22.5% during the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company's stock worth $58,000 after acquiring an additional 32 shares in the last quarter. ORG Partners LLC purchased a new position in ICON Public in the 2nd quarter worth approximately $59,000. Finally, Whittier Trust Co. of Nevada Inc. grew its position in ICON Public by 410.8% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company's stock valued at $63,000 after acquiring an additional 152 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.